Drug Profile

BB 102 - BroadenBio

Alternative Names: BB-102 - BroadenBio

Latest Information Update: 20 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BroadenBio
Class Antineoplastics; Small molecules
Mechanism of Action Type 4 fibroblast growth factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours

Most Recent Events

05 Apr 2024 Pharmacokinetics, pharmacodynamics and adverse events data from preclinical studies in Solid tumours presented at the 115^thAnnual Meeting of the American Association for Cancer Research (AACR-2024)
30 May 2023 Broaden bio plans a phase I trial for Solid tumours in USA by second quarter of 2024 (BroadenBio pipeline, May 2023)
05 Jan 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com